Bushmakin AG - Search Results

1

Improvement of Fatigue in Patients with Ankylosing Spondylitis Receiving Tofacitinib: Analyses of a Phase 3 Randomized Controlled Trial.

Gossec L, Walsh JA, Sengupta R, Bushmakin AG, Cappelleri JC, Yndestad A, Dina O, Cella D. Gossec L, et al. Among authors: bushmakin ag. Rheumatol Ther. 2024 Dec 13. doi: 10.1007/s40744-024-00727-5. Online ahead of print. Rheumatol Ther. 2024. PMID: 39671076 Free article.

2

Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis.

Kristensen LE, Navarro-Compán V, Magrey M, Bushmakin AG, Cappelleri JC, Yndestad A, Dina O, Taylor PC. Kristensen LE, et al. Among authors: bushmakin ag. Rheumatol Ther. 2023 Aug;10(4):1073-1087. doi: 10.1007/s40744-023-00570-0. Epub 2023 Jun 23. Rheumatol Ther. 2023. PMID: 37351781 Free PMC article.

3

The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib.

Bushmakin AG, Mamolo C, Cappelleri JC, Stewart M. Bushmakin AG, et al. J Dermatolog Treat. 2015 Feb;26(1):19-22. doi: 10.3109/09546634.2013.861891. Epub 2013 Dec 2. J Dermatolog Treat. 2015. PMID: 24289224 Free article. Clinical Trial.

4

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.

Cella D, Davis MP, Négrier S, Figlin RA, Michaelson MD, Bushmakin AG, Cappelleri JC, Sandin R, Korytowsky B, Charbonneau C, Matczak E, Motzer RJ. Cella D, et al. Among authors: bushmakin ag. Cancer. 2014 Jun 15;120(12):1871-80. doi: 10.1002/cncr.28660. Epub 2014 Mar 13. Cancer. 2014. PMID: 24634003 Free PMC article. Clinical Trial.

5

Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses.

Mamolo CM, Bushmakin AG, Cappelleri JC. Mamolo CM, et al. Among authors: bushmakin ag. J Dermatolog Treat. 2015 Apr;26(2):121-3. doi: 10.3109/09546634.2014.906033. Epub 2014 Apr 10. J Dermatolog Treat. 2015. PMID: 24716586 Free article. Clinical Trial.

6

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.

Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA. Cella D, et al. Among authors: bushmakin ag. J Patient Rep Outcomes. 2019 Jan 24;3(1):5. doi: 10.1186/s41687-019-0094-5. J Patient Rep Outcomes. 2019. Corrected and republished in: J Patient Rep Outcomes. 2019 May 20;3(1):30. doi: 10.1186/s41687-019-0115-4 Retraction in: J Patient Rep Outcomes. 2019 May 28;3(1):32. doi: 10.1186/s41687-019-0125-2 PMID: 30680661 Free PMC article. Corrected and republished. Retracted.

7

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.

Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA. Cella D, et al. Among authors: bushmakin ag. J Patient Rep Outcomes. 2019 May 20;3(1):30. doi: 10.1186/s41687-019-0115-4. J Patient Rep Outcomes. 2019. PMID: 31111255 Free PMC article.

8

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib.

Coates LC, Bushmakin AG, FitzGerald O, Gladman DD, Fallon L, Cappelleri JC, Hsu MA, Helliwell PS. Coates LC, et al. Among authors: bushmakin ag. Arthritis Res Ther. 2021 Mar 26;23(1):94. doi: 10.1186/s13075-021-02474-2. Arthritis Res Ther. 2021. PMID: 33766074 Free PMC article. Clinical Trial.

9

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.

Gladman DD, Coates LC, Wu J, Fallon L, Bacci ED, Cappelleri JC, Bushmakin AG, Helliwell PS. Gladman DD, et al. Among authors: bushmakin ag. Arthritis Res Ther. 2022 Feb 9;24(1):40. doi: 10.1186/s13075-022-02721-0. Arthritis Res Ther. 2022. PMID: 35139908 Free PMC article.

10

WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee.

Conaghan PG, Dworkin RH, Schnitzer TJ, Berenbaum F, Bushmakin AG, Cappelleri JC, Viktrup L, Abraham L. Conaghan PG, et al. Among authors: bushmakin ag. J Rheumatol. 2022 Jun;49(6):615-621. doi: 10.3899/jrheum.210543. Epub 2022 Mar 1. J Rheumatol. 2022. PMID: 35232805 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters